Asenapine in bipolar I disorder: Evidence and place in patient management

Therapeutic Advances in Chronic Disease

Volumn 4, Issue 1, 2013, Pages 5-14

  Samalin, Ludovic ^a   Charpeaud, Thomas ^a   Llorca, Pierre Michel ^a  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

Antipsychotics; Asenapine; Bipolar disorder; Mania

Indexed keywords

ASENAPINE; CLOZAPINE; HALOPERIDOL; ILOPERIDONE; LITHIUM; LURASIDONE; OLANZAPINE; PALIPERIDONE; PLACEBO; RISPERIDONE; VALPROIC ACID;

AKATHISIA; BIPOLAR DISORDER; BIPOLAR I DISORDER; DEPRESSION; DISEASE EXACERBATION; DRUG APPROVAL; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; DYSLIPIDEMIA; DYSTONIA; ENDOCRINE DISEASE; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; FAINTNESS; GLUCOSE BLOOD LEVEL; HUMAN; HYPESTHESIA; MAINTENANCE THERAPY; MANIA; META ANALYSIS (TOPIC); METABOLIC DISORDER; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PATIENT CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSIS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; SUICIDAL BEHAVIOR; TARDIVE DYSKINESIA; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 84875638287     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622312468933     Document Type: Review

References (33)

1. Azorin J. Sapin C. Weiller E. (2012) Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses. J Affect Disord 4 August (Epub ahead of print).
2. Baruch Y. Tadger S. Plopski I. Barak Y. (2012) Asenapine for elderly bipolar manic patients. J Affect Disord 6 August (Epub ahead of print).
3. Bishara D. Taylor D. (2009) Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder. Neuropsychiatr Dis Treat 5: 483–490.
4. Chwieduk C. Scott L. (2011) Asenapine: a review of its use in the management of mania in adults with bipolar I disorder. CNS Drugs 25: 251–267.
5. Citrome L. (2009) Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract 63: 1762–1784.
6. de Hert M. Yu W. Detraux J. Sweers K. van Winkel R. Correll C. (2012) Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs 26: 733–759.
7. Elsworth J. Groman S. Jentsch J. Valles R. Shahid M. Wong E. et al. (2012) Asenapine effects on cognitive and monoamine dysfunction elicited by subchronic phencyclidine administration. Neuropharmacology 62: 1442–1452.
8. EMEA (2010) Assessment Report Sycrest. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001177/WC500096898.pdf (accessed 7 November 2012).
9. Gonzalez J. Thompson P. Moore T. (2011) Review of the safety, efficacy, and side effect profile of asenapine in the treatment of bipolar 1 disorder. Patient Prefer Adherence 5: 333–341.
10. Goodwin G. (2009) Evidence-based guidelines for treating bipolar disorder: revised second edition–recommendations from the British Association for Psychopharmacology. J Psychopharmacol 23: 346–388.
11. Grunze H. Vieta E. Goodwin G. Bowden C. Licht R. Moller H. et al. (2009) The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 10: 85–116.
12. HAS (2011) Avis de la commission de transparence 2 novembre 2011. http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-12/sycrest_2-11-2011_avis_ct-11050.pdf (accessed 7 November 2012).
13. Hedlund P. (2009) The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology (Berl) 206: 345–354.
14. Henry J. Fuller M. (2011) Asenapine: a new antipsychotic option. J Pharm Pract 24: 447–451.
15. Leucht S. Kissling W. Davis J. (2009) Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med 39: 1591–1602.
16. Llorca P. Courtet P. Martin P. Abbar M. Gay C. Meynard J. et al. (2010) [Screening and management of bipolar disorders: results]. Encephale 36(Suppl. 4): S86–S102.
17. Malhi G. Adams D. Lampe L. Paton M. O'Connor N. Newton L. et al. (2009) Clinical practice recommendations for bipolar disorder. Acta Psychiatr Scand Suppl (439): 27–46.
18. McIntyre R. (2011) Asenapine: a review of acute and extension phase data in bipolar disorder. CNS Neurosci Ther 17: 645–648.
19. McIntyre R. Cohen M. Zhao J. Alphs L. Macek T. Panagides J. (2009 a) A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord 11: 673–686.
20. McIntyre R. Cohen M. Zhao J. Alphs L. Macek T. Panagides J. (2009 b) Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord 11: 815–826.
21. McIntyre R. Cohen M. Zhao J. Alphs L. Macek T. Panagides J. (2010 a) Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. J Affect Disord 126: 358–365.
22. McIntyre R. Cohen M. Zhao J. Alphs L. Macek T. Panagides J. (2010 b) Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord 122: 27–38.
23. McIntyre R.S. Wong R. (2012) Asenapine: a synthesis of efficacy data in bipolar mania and schizophrenia. Clin Schizophr Relat Psychoses 5 (4): 217–220.
24. Pini S. de Queiroz V. Pagnin D. Pezawas L. Angst J. Cassano G.B. et al. (2005) Prevalence and burden of bipolar disorders in European countries. Eur Neuropsychopharmacol 15: 425–434.
25. Pompili M. Venturini P. Innamorati M. Serafini G. Telesforo L. Lester D. et al. (2011) The role of asenapine in the treatment of manic or mixed states associated with bipolar I disorder. Neuropsychiatr Dis Treat 7: 259–265.
26. Samalin L. Tixeront C. Llorca P. (2012) Asenapine in bipolar disorder: efficacy, safety and place in clinical practice. Encephale 38: 257–265.
27. Shahid M. Walker G. Zorn S. Wong E. (2009) Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 23: 65–73.
28. Stoner S. Pace H. (2012) Asenapine: a clinical review of a second-generation antipsychotic. Clin Ther 34: 1023–1040.
29. Szegedi A. Calabrese J. Stet L. Mackle M. Zhao J. Panagides J. ; Apollo Study Group (2012) Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension. J Clin Psychopharmacol 32: 46–55.
30. Szegedi A. Zhao J. van Willigenburg A. Nations K. Mackle M. Panagides J. (2011) Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials. BMC Psychiatry 11: 101.
31. Yatham L. Kennedy S. Schaffer A. Parikh S. Beaulieu S. O'Donovan C. et al. (2009) Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 11: 225–255.
32. Yildiz A. Vieta E. Leucht S. Baldessarini R. (2011) Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology 36: 375–389.
33. Zhao J. Ha X. Szegedi A. (2011) Early improvement predicts later outcome in manic or mixed episodes associated with bipolar I disorder: post hoc analyses of asenapine studies. 9th International Conference on Bipolar Disorder, 9–11 June 2011, Pittsburgh, NJ, USA.